Genmab A/S (GNMSF) Comparison with companies in other sectors?

Genmab A/S has a share price of 61.51M. You can analyze Genmab A/S (GNMSF) competitors across different market sectors through stock heatmaps.

What are GNMSF's NET and operating margins?

Genmab A/S (GNMSF) operating margin is around 0.34, and net profit margin is approximately 0.37 as of the latest reports.

In what way does GNMSF's earnings per share (EPS) trend reflect its financial momentum?

Genmab A/S (GNMSF) EPS is 17.03 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Genmab A/S is 13.32, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Genmab A/S?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Genmab A/S like P/E which is 13.69, P/B which is 17.35, and PEG which is -0.15. Compare them with sector averages to evaluate if the stock is priced fairly.

Genmab A/S

GNMSF•PNK

Healthcare

Biotechnology

$226.84

$1.84(0.82%)

Fundamental Analysis of Genmab A/S (GNMSF)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$17.03

P/E Ratio

13.32

ROE

0.26%

Net Margin

0.37%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$13.95B

Shares OutstandingTotal number of shares issued

$61.51M

Book Value/ShareNet worth per share

$83.11

Revenue/ShareAnnual revenue per share

$284.00

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$17.03

Net MarginNet income as percentage of revenue

37.10%

Operating MarginOperating income as percentage of revenue

33.65%

ROEReturn on shareholders' equity

25.61%

ROAReturn on total assets

101.94%

ROCEReturn on capital employed

104.46%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$97.90

Cash/ShareCash and equivalents per share

$50.62

FCF YieldFree cash flow as percentage of market cap

7.04%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for GNMSFFinancial Ratios Analysis details for GNMSF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for GNMSFSector Benchmarking details for GNMSF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Genmab A/S Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Genmab A/S. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Genmab A/S's unique business strengths and challenges.

Key Financial Metrics for Genmab A/S

For Genmab A/S, essential financial indicators include EPS 17.03, PE 13.32, and ROE 0.26. These key ratios reveal insights into Genmab A/S's profitability, valuation, and operational health. Understanding these metrics enables you to compare Genmab A/S with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Genmab A/S

Metrics like Net Margin 37.10% and ROA 101.94% shed light on how well Genmab A/S is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Genmab A/S can sustain its operations and continue growing in the future.

Valuation and Market Position of Genmab A/S

Using ratios such as P/B Ratio 17.35 and PEG Ratio -0.15, investors can assess whether Genmab A/S is appropriately valued based on its financials and growth potential. These figures, combined with Genmab A/S's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Genmab A/S

Financial health indicators, such as Debt/Equity Ratio 0.03 and Cash Flow $97.90, provide a snapshot of Genmab A/S's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Genmab A/S, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Genmab A/S

Investing in Genmab A/S based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Genmab A/S focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;